CEACAM5 and colorectal carcinoma: The CD151CD63-negative samples were further complemented with the glycovariant assays CEACon-A, CA19.9Con-A, and CA125WGA along with CEA EIA to detect all the early-stage (10 out of 11) and late-stage (8 out of 11) CRC serum samples.